Sanofi-Aventis Zimulti (clarification)
Executive Summary
FDA data analysis presented at a recent advisory committee on rimonabant for weight loss suggests the product has a greater suicidality risk than competitors; it did not specifically address class risk for suicidality (1"The Pink Sheet" June 25, 2007, p. 23). Some of the data presented at the advisory committee session also was drawn from animal studies...